Peptable

Comparison

KPV vs Tirzepatide

Function

While KPV is investigated as an anti-inflammatory and barrier-protective agent in skin and mucosal models, reducing pro-inflammatory cytokines and promoting tissue repair684, Tirzepatide is approved for type 2 diabetes and obesity, producing larger HbA1c and body-weight reductions than semaglutide in head-to-head trials24.

Mechanism

While KPV works as the C-terminal Lys-Pro-Val tripeptide fragment of α-MSH, which exerts potent anti-inflammatory effects largely via inhibition of NF-κB signaling and modulation of cytokine expression, with many actions independent of classical melanocortin receptor activation684, Tirzepatide is a 39-amino-acid synthetic peptide primarily based on GIP sequence with C20 fatty diacid conjugation that acts as a dual agonist at GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite24.

Receptor

KPV

No single primary receptor; the KPV motif can influence melanocortin receptor binding profiles (MC1R–MC5R), but many anti-inflammatory effects appear melanocortin-independent684

Tirzepatide

Glucose-dependent insulinotropic polypeptide receptor (GIPR) and GLP-1 receptor (GLP1R) 24

Organism or Origin

KPV

Endogenous tripeptide corresponding to positions 11–13 of human α-MSH8490

Tirzepatide

Synthetic dual GIP/GLP-1 receptor agonist modeled on human incretin hormones2480

Gene

KPV

POMC

Tirzepatide

Not assigned in the current dataset.

Summary

KPV and Tirzepatide are noticeably different, with limited direct overlap in their usual biological context. Their typical research and application settings separate fairly clearly: KPV is more often discussed in the realm of Immunology and inflammation, Gastroenterology, and Dermatology and aesthetics, whereas Tirzepatide is more often associated with the realm of Metabolic and endocrine and Cardiovascular health. They also influence different molecular systems, with KPV tracking more closely to Melanocortin receptor while Tirzepatide centers more on GLP-1 receptor. KPV has a more natural endogenous origin, while Tirzepatide is closer to synthetic analog background and their development context also differs, with KPV in Preclinical development while Tirzepatide is approved. KPV takes the form of a linear peptide, whereas Tirzepatide is closer to a peptide conjugate, Tirzepatide incorporates lipidation and d-amino acid substitution features that are not part of KPV; while their sequence patterns also diverge, with KPV showing protein-mimetic sequence features and Tirzepatide showing alpha-helical domain features.

Sources

6Keratinocyte And Dermal..., https://oathresearch.com/2026/03/27/kpv-tripeptide-nfkb-inhibition-anti-inflammatory-mechanisms-cell-culture/
90alpha-Melanocyte stimulating hormone: production and degradation, https://pmc.ncbi.nlm.nih.gov/articles/PMC3936413/
24Tirzepatide - a dual GIP and GLP-1 (GLP1) receptor agonist, https://gpnotebook.com/pages/diabetes-and-endocrinology/tirzepatide-a-dual-gip-and-glp-1-glp1-receptor-agonist
80GLP-1 Localisation and Proglucagon Gene Expression in ..., https://pmc.ncbi.nlm.nih.gov/articles/PMC6200298/